Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | ICMT | O60725 | 5/20 | 0.34 |
| ▸ | EDNRB | P24530 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.34 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 4/20 | 0.31 |
| ▸ | PPARA | Q07869 | 4/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7314014 | 0.79 | HTR6 (0.35) | HTR6ICMTHTR2CNTSR1MCL1 | |
| SCHEMBL7306862 | 0.78 | HTR6 (0.35) | HTR6ICMTHTR2CNTSR1TLR4 | |
| SCHEMBL7318525 | 0.77 | NTSR1 (0.38) | HTR6ICMTNTSR1MCL1ACMSD | |
| SCHEMBL7312233 | 0.75 | HTR6 (0.36) | HTR6ICMTNTSR1MCL1ACMSD | |
| SCHEMBL7315194 | 0.75 | HTR6 (0.36) | HTR6ICMTNTSR1MCL1ACMSD | |
| SCHEMBL7316939 | 0.74 | OPRM1 (0.36) | HTR6ICMTNTSR1MCL1ACMSD | |
| SCHEMBL7305101 | 0.73 | CYP19A1 (0.35) | HTR6ICMTNTSR1MCL1 | |
| SCHEMBL7314992 | 0.73 | TSPO (0.46) | HTR6ICMTMCL1 | |
| SCHEMBL7320265 | 0.72 | ICMT (0.45) | HTR6ICMTMCL1PPARG | |
| Trifluoroacetic Acid SCHEMBL7318294 | 0.66 | NTSR1 (0.45) | HTR6ICMTNTSR1MCL1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | claimed |
| US-20020004198-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2002-01-10 | — | — | US | disclosed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | HTR6 4503/4885ICMT 1459/4885EDNRB 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.